Dpp4 - dipeptidylpeptidase 4 Gene
Also Known as Cd26; THAM; Dpp-4
生物種: Mus musculus
遺伝子タイプ: protein coding
遺伝子ID: 13482
About Dpp4
Chromosome 2: 62,160,417-62,242,575 reverse strand.GRCm39:CM000995.3
This gene has 6 transcripts (splice variants), 286 orthologues, 6 paralogues and is associated with 31 phenotypes. Biased expression in large intestine adult (RPKM 3.2), small intestine adult (RPKM 11.7) and 11 other tissues.
Summary
Predicted to enable several functions, including chemorepellent activity; peptidase activity; and protein homodimerization activity. Acts upstream of or within behavioral fear response; locomotory exploration behavior; and psychomotor behavior. Located in intercellular canaliculus. Is expressed in several structures, including genitourinary system; inner ear; intraembryonic coelom; liver; and primitive heart tube. Used to study Middle East respiratory syndrome. Human ortholog(s) of this gene implicated in Middle East respiratory syndrome and type 2 diabetes mellitus. Orthologous to human DPP4 (Dipeptidyl Peptidase 4). [provided by Alliance of Genome Resources, Apr 2022]
Dpp4 Products (2)
| mRNA | Protein | Name |
|---|---|---|
| NM_001159543.1 | NP_001153015.1 | dipeptidyl peptidase 4 isoform 2 |
| NM_010074.3 | NP_034204.1 | dipeptidyl peptidase 4 isoform 1 |
| Biological Process GO Annotation | Evidence | 参考文献 | 由来 |
|---|---|---|---|
| acts upstream of or within behavioral fear response |
IMP
IMP: Inferred from mutant phenotype
|
16712972 | MGI |
| acts upstream of or within locomotory exploration behavior |
IMP
IMP: Inferred from mutant phenotype
|
16712972 | MGI |
| acts upstream of or within psychomotor behavior |
IMP
IMP: Inferred from mutant phenotype
|
16712972 | MGI |
| Cellular Component GO Annotation | Evidence | 参考文献 | 由来 |
|---|---|---|---|
| located in intercellular canaliculus |
IDA
IDA: Inferred from direct assay
|
12068294 | MGI |
EXP: Inferred from Experiment
IDA: Inferred from direct assay
IPI: Inferred from physical interaction
IMP: Inferred from mutant phenotype
IGI: Inferred from genetic interaction
IEP: Inferred from expression pattern
Dpp4 Protein Structure
DPPIV_rep
DPPIV_rep: pfam18811 (35 - 55)
DPPIV_N
DPPIV_N: pfam00930 (101 - 471)
Peptidase_S9
Peptidase_S9: pfam00326 (552 - 756)
- 0
- 200
- 400
- 600
- 760 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
dipeptidyl peptidase 4 |
|
|
Recombinant Dpp4 Proteins
| 製品番号 | 製品名 | アクセッション番号 | 純度 |
|---|---|---|---|
| HY-P75429 | CD26/Dipeptidyl Peptidase 4 Protein, Mouse (HEK293, Fc) | P28843 (S29-H760) | ≥ 95%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(23)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-13749 | Sitagliptin | Inhibitor | 99.94% | Yes |
| HY-10284 | Linagliptin | 99.74% | Unkown | |
| HY-13749A | Sitagliptin phosphate | Inhibitor | 99.88% | Yes |
| HY-10285 | Saxagliptin | Inhibitor | 99.96% | Yes |
| HY-A0023A | Alogliptin | Inhibitor | 99.93% | Unkown |
| HY-14806B | Teneligliptin hydrobromide hydrate | 99.97% | Unkown | |
| HY-14806 | Teneligliptin | Inhibitor | 99.79% | Unkown |
| HY-14806A | Teneligliptin hydrobromide | 99.99% | Unkown | |
| HY-15408 | Trelagliptin | Inhibitor | 99.81% | Unkown |
| HY-15981 | Omarigliptin | Inhibitor | 99.96% | Unkown |
| HY-13749B | Sitagliptin phosphate monohydrate | Inhibitor | 99.83% | Yes |
| HY-14877 | Anagliptin | Inhibitor | 99.92% | Unkown |
| HY-A0023 | Alogliptin Benzoate | Inhibitor | 99.98% | Unkown |
| HY-15408A | Trelagliptin succinate | Inhibitor | 99.87% | Unkown |
| HY-108795 | Albiglutide fragment | Agonist | 99.86% | Unkown |
| HY-16448 | Saxagliptin hydrochloride | Inhibitor | 99.54% | Yes |
| HY-10285A | Saxagliptin hydrate | Inhibitor | ≥99.0% | Yes |
| HY-14892 | Gemigliptin | Inhibitor | / | Unkown |
| HY-13749AR | Sitagliptin phosphate (Standard) | Inhibitor | 99.82% | Unkown |
| HY-108795A | Albiglutide fragment TFA | Agonist | 99.12% | Unkown |
| HY-14877A | Anagliptin hydrochloride | Inhibitor | / | Unkown |
| HY-13749E | Sitagliptin hydrochloride | Inhibitor | / | Unkown |
| HY-13749R | Sitagliptin (Standard) | Inhibitor | / | Unkown |
阻害性抗体
(3)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-P5311 | Albiglutide | Agonist | 99.92% | Unkown |
| HY-P9805 | Anti-MERS-3A1 mAb | Inhibitor | ≥99.0% | Unkown |
| HY-P9806 | Anti-MERS-D12 mAb | Inhibitor | / | Unkown |
Clinical Phase
Bioactive Molecules
(15)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Phase
|
|---|---|---|---|---|
| HY-117985B | Evogliptin tartrate | 98.11% | Phase 4 | |
| HY-14806S | Teneligliptin-d8 | Inhibitor | / | Phase 4 |
| HY-117985 | Evogliptin | / | Phase 4 | |
| HY-112668 | Retagliptin phosphate | Inhibitor | 99.71% | Phase 3 |
| HY-147257 | Cofrogliptin | Inhibitor | 99.29% | Phase 3 |
| HY-10286 | Dutogliptin | Inhibitor | 99.21% | Phase 3 |
| HY-10286A | Dutogliptin tartrate | Inhibitor | / | Phase 3 |
| HY-112668B | Retagliptin hydrochloride | Inhibitor | / | Phase 3 |
| HY-125330 | Denagliptin tosylate | Inhibitor | / | Phase 3 |
| HY-167680 | Denagliptin | / | Phase 3 | |
| HY-10288 | Melogliptin | Inhibitor | / | Phase 2 |
| HY-139792 | Besigliptin tosylate | / | Phase 2 | |
| HY-12528 | DBPR108 | Inhibitor | 99.93% | Phase 1 |
| HY-122188 | TAK-100 | Inhibitor | / | Phase 1 |
| HY-16656 | BMS-767778 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(92)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-P1141 | GLP-1(9-36)amide | Antagonist | 99.69% | Unkown |
| HY-14892A | Gemigliptin tartrate | Inhibitor | 99.52% | Unkown |
| HY-112668A | Retagliptin | Inhibitor | 98.51% | Unkown |
| HY-P1141A | GLP-1(9-36)amide TFA | Antagonist | 98.61% | Unkown |
| HY-N6079 | Timosaponin A1 | Inhibitor | 99.70% | Unkown |
| HY-P4344 | Met-Gly-Pro-AMC | Substrate | 99.74% | Unkown |
| HY-10284S | Linagliptin-d4 | 99.9% | Unkown | |
| HY-14892B | Gemigliptin tartrate hydrate | Inhibitor | 99.83% | Unkown |
| HY-W003222 | N-tert-Boc-cis-4-fluoro-L-proline | 99.0% | Unkown | |
| HY-171454 | DA-1241 | Agonist | 99.18% | Unkown |
| HY-13749AS | Sitagliptin-d4 phosphate | Inhibitor | 99.48% | Unkown |
| HY-13749S1 | Sitagliptin-d4 hydrochloride | Inhibitor | 99.36% | Unkown |
| HY-158315 | NZ-97 | Inhibitor | 99.43% | Unkown |
| HY-123377A | Fotagliptin benzoate | Inhibitor | 99.19% | Unkown |
| HY-147401 | Sitagliptin fenilalanil | Inhibitor | 99.57% | Unkown |
| HY-131250 | N-Boc-Sitagliptin | 98.87% | Unkown | |
| HY-RS03963 | DPP4 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W003592A | L-Orinithine lactam hydrochloride | 97.0% | Unkown | |
| HY-123377 | Fotagliptin | Inhibitor | 99.05% | Unkown |
| HY-147401A | Sitagliptin fenilalanil hydrochloride | Inhibitor | 98.94% | Unkown |
| HY-A0023AS1 | Alogliptin-d3 | Inhibitor | 99.61% | Unkown |
| HY-124958 | NDMC101 | Inhibitor | 99.91% | Unkown |
| HY-A0023AS | Alogliptin-13C,d3 | Inhibitor | / | Unkown |
| HY-I0786 | (2S,4R)-Teneligliptin | Inhibitor | / | Unkown |
| HY-117985A | Evogliptin hydrochloride | Inhibitor | / | Unkown |
| HY-170569 | Cetagliptin | / | Unkown | |
| HY-10284S1 | Linagliptin-13C,d3 | / | Unkown | |
| HY-10284S3 | Linagliptin-d3-1 | / | Unkown | |
| HY-10285S | Saxagliptin-15N,d2 hydrochloride | Inhibitor | / | Unkown |
| HY-10287A | Gosogliptin hydrochloride | Inhibitor | / | Unkown |
| HY-103432 | DPP4-In | / | Unkown | |
| HY-111294 | ASP4000 hydrochloride | Inhibitor | / | Unkown |
| HY-117985BS | Evogliptin-d9 tartrate | / | Unkown | |
| HY-121029 | Bisegliptin | / | Unkown | |
| HY-13749C | (S)-Sitagliptin phosphate | Inhibitor | / | Unkown |
| HY-13749S2 | Sitagliptin-d4 | Inhibitor | / | Unkown |
| HY-146455 | DPP-4-IN-3 | Inhibitor | / | Unkown |
| HY-146468 | DPP-4/GPR119 modulator 1 | / | Unkown | |
| HY-146469 | DPP-4/GPR119 modulator 2 | / | Unkown | |
| HY-14806S1 | Teneligliptin-d4 | Inhibitor | / | Unkown |
| HY-14892C | Gemigliptin hydrochloride | Inhibitor | / | Unkown |
| HY-151383 | DPP-4-IN-1 | Inhibitor | / | Unkown |
| HY-151384 | DPP-4-IN-2 | Inhibitor | / | Unkown |
| HY-153522 | ZY15557 | Inhibitor | / | Unkown |
| HY-15408S | Trelagliptin-13C,d3 | Inhibitor | / | Unkown |
| HY-155027 | DPP-4-IN-8 | Inhibitor | / | Unkown |
| HY-155961 | Antidiabetic agent 2 | Inhibitor | / | Unkown |
| HY-157390 | DPP-4-IN-9 | Inhibitor | / | Unkown |
| HY-159491 | DPP-4-IN-11 | Inhibitor | / | Unkown |
| HY-161428 | ZINC000003015356 | Inhibitor | / | Unkown |
| HY-162513 | DPP-4-IN-10 | Inhibitor | / | Unkown |
| HY-163332 | MPO-IN-6 | Inhibitor | / | Unkown |
| HY-168621 | DPP-4-IN-13 | Inhibitor | / | Unkown |
| HY-169110 | DPP-4-IN-12 | Inhibitor | / | Unkown |
| HY-170572 | PB01 | Inhibitor | / | Unkown |
| HY-170657 | DPP-4-IN-14 | Inhibitor | / | Unkown |
| HY-176000 | Sulphostin | Inhibitor | / | Unkown |
| HY-179348 | DPP9-IN-2 | / | Unkown | |
| HY-179473 | MK-0626 | / | Unkown | |
| HY-182336 | DeDPP4 | / | Unkown | |
| HY-184139 | KGDI-109 | Inhibitor | / | Unkown |
| HY-N9725 | 16-Hydroxycleroda-3,13-dien-15,16-olide | Inhibitor | / | Unkown |
| HY-P10760 | PhAc-ALGP-Dox | / | Unkown | |
| HY-P11823 | FAPα/DPP4 flurogenic substrate-1 | / | Unkown | |
| HY-P6177 | SGP8 | Inhibitor | / | Unkown |
| HY-RS03964 | Dpp4 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS03965 | Dpp4 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W741755A | 5-Hydroxy saxagliptin hydrochloride | Inhibitor | / | Unkown |
| HY-W741755S1 | 5-Hydroxy saxagliptin-13C,d2-2 hydrochloride | Inhibitor | / | Unkown |
| HY-Z1764 | DPP-4-IN-18 | Inhibitor | / | Unkown |
| HY-10284S4 | Linagliptin-d5 | / | Unkown | |
| HY-10284S5 | Linagliptin-d6 | / | Unkown | |
| HY-10285S2 | Saxagliptin-13C2 | Inhibitor | / | Unkown |
| HY-109060 | Garvagliptin | Inhibitor | / | Unkown |
| HY-110051 | DPP4-In hydrochloride | / | Unkown | |
| HY-117985S | Evogliptin-d9 | / | Unkown | |
| HY-119266 | HTS13517 | Inhibitor | / | Unkown |
| HY-132489S | (Rac)-Sitagliptin-d4 | Inhibitor | / | Unkown |
| HY-132489S1 | (Rac)-Sitagliptin-d4-1 hydrochloride | Inhibitor | / | Unkown |
| HY-13749D | (Rac)-Sitagliptin | Inhibitor | / | Unkown |
| HY-13749S3 | Sitagliptin-d6 | Inhibitor | / | Unkown |
| HY-14806S2 | Teneligliptin-d5 | Inhibitor | / | Unkown |
| HY-14877S1 | Anagliptin-d7 | Inhibitor | / | Unkown |
| HY-170800 | DPP-4-IN-15 | Inhibitor | / | Unkown |
| HY-174832 | DPP-4-IN-16 | Inhibitor | / | Unkown |
| HY-175590 | DPP-4-IN-17 | Inhibitor | / | Unkown |
| HY-180527 | SGLT2-IN-5 | Inhibitor | / | Unkown |
| HY-180528 | SGLT2-IN-6 | Inhibitor | / | Unkown |
| HY-A0299A | H-Gly-Pro-Hyp-OH acetate | Inhibitor | 99.9% | Unkown |
| HY-N4069 | Lupinalbin A | / | Unkown | |
| HY-N8134 | 2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one | Inhibitor | 99.70% | Unkown |
| HY-Z3637 | (–)-Sitagliptin carbamoyl glucuronide | Control | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service